Gemcitabine 100 mg/ml Concentrate for Solution for Infusion

DRUG3 trials

Sponsors

AstraZeneca AB, Actuate Therapeutics Limited

Conditions

Advanced Biliary Tract CancersRefractory Hematologic Malignancies or Solid Tumors

Phase 1

Actuate 1801: Phase 1/2 Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies or Solid Tumors

Active, not recruitingCTIS2024-518409-16-00

Actuate Therapeutics LimitedRefractory Hematologic Malignancies or Solid Tumors

Start: 2021-04-14Target: 225Updated: 2025-08-19

Phase 3

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)

WithdrawnCTIS2022-502043-35-00

AstraZeneca ABAdvanced Biliary Tract Cancers

Target: 76Updated: 2023-09-04

A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE)

Active, not recruitingCTIS2022-502043-35-01

AstraZeneca ABAdvanced Biliary Tract Cancers

Start: 2024-04-24Target: 76Updated: 2025-11-26